VMAT vs. 7-Field-IMRT: Assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample

Medical Dosimetry

Volumn 36, Issue 4, 2011, Pages 365-372

  Kopp, Robert W ^a   Duff, Michael ^b   Catalfamo, Frank ^b   Shah, Dhiren ^b   Rajecki, Michael ^b   Ahmad, Kehkashan ^c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b Cancer Care of Western New York ^*  (United States)

^c UNIVERSITY OF WISCONSIN LA CROSSE   (United States)

Author keywords

IMRT; Prostate cancer; RapidArc; VMAT

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FEMUR HEAD; FIXED FIELD INTENSITY MODULATED RADIATION THERAPY; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PENIS; PENIS BULB; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RECTUM; RETROSPECTIVE STUDY; TREATMENT PLANNING; VOLUMETRIC MODULATED ARC THERAPY; VOLUMETRY;

AGED; FEMUR HEAD; FIDUCIAL MARKERS; HUMANS; MALE; MIDDLE AGED; PENIS; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URINARY BLADDER;

EID: 80054735238     PISSN: 09583947     EISSN: 18734022     Source Type: Journal    
DOI: 10.1016/j.meddos.2010.09.004     Document Type: Article

References (41)

1. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation in clinically localized adenocarcinoma of the prostate: a randomized control trial. JAMA 2005, 294:1233-1239.
2. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomized controlled trial. Lancet Oncol 2007, 8:475-487.
3. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol 2006, 24:1990-1996.
4. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys 2002, 53:1097-1105.
5. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int. J. Radiat. Oncol. Biol. Phys 1998, 41:83-92.
6. Abrahim A.M., Wilma W.D., Peeters S.T., et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2009, 73:685-691.
7. Fonteyne V., Villeirs G., Speleers B., et al. Intensity-modulated radiotherapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int. J. Radiat. Oncol. Biol. Phys 2008, 72:799-807.
8. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control, prognostic factors and toxicities in patients treated with intensity modulated radiotherapy for localized prostate cancer with longer follow-up. Int. J. Radiat. Oncol. Biol. Phys 2008, 72:S1.
9. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol 2001, 166:876-881.
10. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2002, 54:1314-1321.
11. Kupelian P.A., Redy C.A., Carlson T.P., et al. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?. Cancer J 2002, 8:62-66.
12. Abrahim A.M., Heemsbergen W.D., Peeters S.T.H., et al. Role of intensity-modulated radiotherapy in dose escalation for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2009, 73:685-691.
13. Peeters S.T.H., Heemsberger W.D., van Putten W.L.J., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int. J. Radiat. Oncol. Biol. Phys 2005, 61:1019-1034.
14. Popescu C.C., Wai E.S., Ansbacher W., et al. Volumetric modulated arc therapy reduces treatment time compared to 9-field conventional intensity modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:S521.
15. Bendorffe B., Larsson S., Beckham W., et al. A comparison of VMAT with cIMRT plans for squamous cell carcinomas of the oropharynx. Int. J. Radiat. Oncol. Biol. Phys 2008, 72(Suppl):S24. S24.
16. Afghan M.K.N., Cao D., Mehta V., et al. Volumetric modulated arc therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2008, 72(Suppl):S665-S666.
17. Shepard D.M., Cao D., Afghan M.K.N., et al. Dysphagia optimized head and neck volumetric modulated arc therapy. Int. J. Radiat. Oncol. Biol. Phys 2008, 72(Suppl):S25.
18. Wolff D., Stieler F., Abo-Madyan Y., et al. Volumetric intensity modulated arc therapy (VMAT) vs. serial tomotherapy and segmental (step and shoot) IMRT for treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2008, 72(Suppl):S562.
19. Shaffer R.E., Nichol A., Vollans E., et al. Volumetric modulated arc therapy (VMAT) reduces treatment time and improves dosimetry compared to conventional intensity modulated radiotherapy (IMRT) for frontal and temporal high-grade gliomas (HGG). Int. J. Radiat. Oncol. Biol. Phys 72 2008, (Suppl):S533.
20. Palma D., Vollans E., James K., et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys 2008, 72:996-1001.
21. Palma D., Vollans E., James K., et al. Volumetric modulated arc therapy for delivery of prostate RT: reduction in treatment time and monitor unit requirements compared to IMRT. Int. J. Radiat. Oncol. Biol. Phys 2008, 72(Suppl):S312.
22. Zhang P., Happersett L., Hunt M., et al. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int. J. Radiat. Oncol. Biol. Phys 2009, 76:1456-1462.
23. Bragg C.M., Wingate K., Conway J. Clinical implications of the anisotropic analytical algorithm for IMRT treatment planning and verification. Radiother. Oncol 2007, 86:276-284.
24. A phase III randomized study of high dose 3D-CRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated or localized prostate cancer Radiation Therapy Oncology Group, RTOG 0126, Accessed: August 28, 2010. http://www.rtog.org/members/protocols/0126/p0126.pdf.
25. Kupelian P.A., Buchsbaum J.C., Elshaikh M.A., et al. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. Int. J. Radiat. Oncol. Biol. Phys 2003, 57:629-634.
26. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br. J. Cancer 2005, 92:488-498.
27. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys 2002, 53:1111-1116.
28. Fonteyne V., Villeirs G., Speleers B., et al. Intensity modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int. J. Radiat. Oncol. Biol. Phys 2008, 72:799-807.
29. Peeters S.T.H., Hoogeman M.S., Heemsbergen W.D., et al. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2005, 63:1142-1152.
30. Harsolia A., Vargas C., Yan D., et al. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive 3D-CRT: dose-volume analysis of a phase II dose-escalation study. Int. J. Radiat. Oncol. Biol. Phys 2007, 69:1100-1109.
31. Chan L.W., Ping X., Gottschalk A.R. Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer. Radiother. Oncol 2008, 72:69-77.
32. Fiorino C., Fellin G., Rancati T., et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int. J. Radiat. Oncol. Biol. Phys 2008, 70:1130-1137.
33. Marzi S., Arcangeli G., Saracino B., et al. Relationship between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2007, 68:41-49.
34. Van der Wielen M.J.P., Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother. Oncol 2007, 84:107-113.
35. Mangar S.A., Sydes M.R., Tucker H.L., et al. Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomized controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). Radiother. Oncol 2006, 80:355-362.
36. Wernicke A.G., Valicenti R., DiEva K., et al. Radiation dose delivered to the proximal penis as a predictor of erectile dysfunction after 3D-CRT for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys 2004, 60:1357-1363.
37. Roach M., Winter K., Michalski J.M., et al. Penile bulb dose and impotence after 3D-CRT for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. Int. J. Radiat. Oncol. Biol. Phys 2004, 60:1351-1356.
38. Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med. Phys 2008, 35:310-317.
39. Little D.J., Dong L., Levy L.B., et al. Use of portal images and BAT ultrasound to measure setup error and organ motion for prostate IMRT: implications for treatment margins. Int. J. Radiat. Oncol. Biol. Phys 2003, 56:1218-1224.
40. Litzenberg D.W., Balter J.M., Hadley S.W., et al. Influence of intrafraction motion on margins for prostate radiotherapy. Int. J. Radiat. Oncol. Biol. Phys 2006, 65:548-553.
41. Nederveen A.J., van der Heide U.A., Dehnad H., et al. Measurements and clinical consequences of prostate motion during radiotherapy fraction. Int. J. Radiat. Oncol. Biol. Phys 2002, 53:206-214.